1 results about "OPHTHALMIC DISORDERS" patented technology

This invention discloses the application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome, relating to the field of biomedical technology. The application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome. This invention is the first to discover the application of the Wnt-β-catenin pathway inhibitor LGK974 in the treatment of dry eye syndrome. LGK974, by inhibiting the Wnt-β-catenin pathway, can effectively protect meibomian gland acini and ducts, restoring normal lipid metabolism and secretion. In a NOD (Normally Ophthalmic Disorder) Sjögren's syndrome model, oral administration of 200-400 μg / kg / day of LGK974 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, alleviating morphological and functional damage to the meibomian glands. LGK974 provides a new targeted strategy for the treatment of dry eye syndrome, especially Sjögren's syndrome-related dry eye syndrome and meibomian gland dysfunction-related dry eye syndrome, and may become a potent and effective drug for the clinical treatment of dry eye in the future.